Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity

LEXINGTON, Mass., Sept. 18, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the company was awarded U.S. Patent 8,268,971, entitled "Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity."

The patent covers milk derived antibody compositions that specifically target and modulate an apical intestinal receptor and which are formulated for direct delivery to the gastrointestinal tract of a patient.  The patent also covers treatment of diabetes or obesity by using these antibodies to modulate a sugar receptor.  The types of intestinal receptors disclosed in the patent are very broad, and include sugar transporters, ion channels, sensors, and bile acid transporters.

"This patent highlights the broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "Our oral antibodies can address membrane bound targets as well as soluble targets such as TNF for inflammatory bowel disease and radiation induced damage to the mouth and intestines.  Membrane bound targets such as sugar transporters have been implicated in diabetes and obesity, which are very attractive markets for our oral antibodies."

About Avaxia Biologics:

Avaxia is developing orally administered antibody therapeutics that act locally within the digestive tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are injected or infused rather than administered orally because they are destroyed in the digestive tract.  In contrast, we have developed proprietary antibodies that resist digestion.  Our lead product is an oral antibody against tumor necrosis factor (TNF) for inflammatory bowel disease (IBD).  Existing anti-TNF drugs have proven effective for IBD but have serious immunosuppression side effects because they affect the entire body, not just the gastrointestinal (GI) tract where the inflammation occurs.  The goal of our IBD program is to deliver our anti-TNF antibody locally in the GI tract to minimize side effects from systemic drug exposure.  Avaxia also has programs in GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.

SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
2. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
3. South and Central America Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
5. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
6. CMC Biologics Announces Mark W. Sawicki as Vice President, Global Business Development
7. Brazil Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
8. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
9. Synthetic Biologics Reports Second Quarter 2012 Financial Results
10. Global Spinal Devices and Biologics Market 2011-2015
11. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):